AI Engines For more Details: Perplexity Kagi Labs You
Hyperlipidemia: Bezafibrate is primarily used to lower elevated levels of lipids, including cholesterol and triglycerides, in the blood. It works by activating peroxisome proliferator-activated receptors (PPARs), which regulate lipid metabolism. By increasing the breakdown of triglycerides and promoting the removal of cholesterol from the blood, bezafibrate helps reduce the risk of cardiovascular diseases associated with high lipid levels.
Hypertriglyceridemia: Elevated triglyceride levels in the blood are a risk factor for cardiovascular disease. Bezafibrate helps lower triglyceride levels by enhancing the clearance of triglyceride-rich lipoproteins from the blood and inhibiting their synthesis in the liver. It is particularly effective in treating moderate to severe hypertriglyceridemia, either as monotherapy or in combination with other lipid-lowering medications.
Mixed Dyslipidemia: Mixed dyslipidemia refers to a combination of elevated levels of cholesterol and triglycerides in the blood. Bezafibrate is effective in treating mixed dyslipidemia by targeting both cholesterol and triglyceride abnormalities. It helps improve the overall lipid profile and reduce the risk of cardiovascular events in individuals with mixed dyslipidemia.
Atherosclerosis: Atherosclerosis is a condition characterized by the buildup of plaque in the arteries, leading to narrowed and hardened arteries. High levels of cholesterol and triglycerides contribute to the development of atherosclerosis. By lowering lipid levels, bezafibrate may help slow down the progression of atherosclerosis and reduce the risk of complications such as heart attacks and strokes.
Coronary Heart Disease (CHD): Coronary heart disease, also known as coronary artery disease, occurs when the coronary arteries become narrowed or blocked due to atherosclerosis, reducing blood flow to the heart muscle. Lowering lipid levels with medications like bezafibrate can help reduce the risk of CHD events, including angina (chest pain) and myocardial infarction (heart attack), especially in individuals with existing cardiovascular risk factors.
Peripheral Arterial Disease (PAD): Peripheral arterial disease is a condition characterized by narrowed arteries in the legs, leading to reduced blood flow to the lower extremities. Elevated lipid levels contribute to the development and progression of PAD. Bezafibrate may help improve symptoms and outcomes in individuals with PAD by lowering lipid levels and improving blood flow to the legs.
Diabetes Mellitus: Bezafibrate has been shown to have beneficial effects on glucose metabolism and insulin sensitivity in individuals with diabetes mellitus. It may help improve glycemic control and reduce the risk of cardiovascular complications in diabetic patients with dyslipidemia.
Liver Disorders: Bezafibrate has been investigated for its potential role in the treatment of certain liver disorders, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). By reducing lipid accumulation in the liver and improving liver function, bezafibrate may help alleviate liver damage associated with these conditions.
Adverse Effects: Common side effects of bezafibrate include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal discomfort. It may also cause muscle pain or weakness (myopathy) and liver function abnormalities in some individuals. Rare but serious side effects include rhabdomyolysis (muscle breakdown) and liver toxicity. Patients should be monitored regularly for side effects during treatment.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 4 | 0.3 | 12.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.3 | 2.5 | 0.32 |
| Allergies | 5.2 | 2.6 | 1 |
| Allergy to milk products | 1.7 | 1.6 | 0.06 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 5.2 | 4.1 | 0.27 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.9 | 1.56 |
| Ankylosing spondylitis | 3.7 | 1.1 | 2.36 |
| Anorexia Nervosa | 1.3 | 1.8 | -0.38 |
| Antiphospholipid syndrome (APS) | 1.3 | 1.3 | |
| Asthma | 3.9 | 3 | 0.3 |
| Atherosclerosis | 1.7 | 1.7 | 0 |
| Atrial fibrillation | 2.3 | 1.6 | 0.44 |
| Autism | 7.1 | 6.6 | 0.08 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.4 | 2.4 | |
| Bipolar Disorder | 1.5 | 0.8 | 0.88 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 1 | 1 | |
| Cancer (General) | 0.9 | 2.4 | -1.67 |
| Carcinoma | 3.9 | 2.3 | 0.7 |
| Celiac Disease | 2.4 | 2.6 | -0.08 |
| Cerebral Palsy | 1.5 | 1 | 0.5 |
| Chronic Fatigue Syndrome | 3.7 | 3 | 0.23 |
| Chronic Kidney Disease | 4.1 | 1 | 3.1 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.4 | 0.36 |
| Chronic Urticaria (Hives) | 1.9 | 0.4 | 3.75 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1 | 0.9 |
| Cognitive Function | 2.9 | 1.6 | 0.81 |
| Colorectal Cancer | 6.7 | 2.5 | 1.68 |
| Constipation | 1.1 | 0.7 | 0.57 |
| Coronary artery disease | 2.2 | 1.6 | 0.38 |
| COVID-19 | 7.8 | 7.2 | 0.08 |
| Crohn's Disease | 6.8 | 3.7 | 0.84 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 1.1 | 1.9 | -0.73 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.4 | 1.1 | 1.18 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 8.1 | 6.9 | 0.17 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.2 | 1.5 | 0.47 |
| Endometriosis | 3.2 | 1.7 | 0.88 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.5 | 2.2 | 0.59 |
| erectile dysfunction | 2.4 | 0.3 | 7 |
| Fibromyalgia | 3.2 | 0.9 | 2.56 |
| Functional constipation / chronic idiopathic constipation | 4.3 | 2.5 | 0.72 |
| gallstone disease (gsd) | 3.3 | 1.3 | 1.54 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.5 | 1.4 |
| Generalized anxiety disorder | 2.8 | 1.9 | 0.47 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.7 | 0.4 | 3.25 |
| Graves' disease | 1.6 | 2.7 | -0.69 |
| Gulf War Syndrome | 0.6 | 0.9 | -0.5 |
| Halitosis | 1.6 | 0.3 | 4.33 |
| Hashimoto's thyroiditis | 2.6 | 0.8 | 2.25 |
| Heart Failure | 3.9 | 1.2 | 2.25 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.9 | 0.3 | 5.33 |
| hypercholesterolemia (High Cholesterol) | 1 | 0.4 | 1.5 |
| hyperglycemia | 2.2 | 1.7 | 0.29 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.9 | 3 | 0.3 |
| Hypothyroidism | 0.2 | 0.4 | -1 |
| Hypoxia | 3.7 | 0.3 | 11.33 |
| IgA nephropathy (IgAN) | 1.3 | 3 | -1.31 |
| Inflammatory Bowel Disease | 7.6 | 6 | 0.27 |
| Insomnia | 1.6 | 2.1 | -0.31 |
| Intelligence | 1.2 | 1.2 | |
| Intracranial aneurysms | 1.1 | 0.6 | 0.83 |
| Irritable Bowel Syndrome | 6.9 | 4.2 | 0.64 |
| ischemic stroke | 2.6 | 1.4 | 0.86 |
| Liver Cirrhosis | 5.7 | 4.5 | 0.27 |
| Long COVID | 5.3 | 4.9 | 0.08 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1.2 | 1.1 | 0.09 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.3 | 0.3 | 3.33 |
| ME/CFS with IBS | 0.6 | 0.9 | -0.5 |
| ME/CFS without IBS | 1 | 1.6 | -0.6 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.7 | 0.7 | 1.43 |
| Metabolic Syndrome | 6.6 | 6 | 0.1 |
| Mood Disorders | 8.1 | 5.2 | 0.56 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 5.4 | 3.2 | 0.69 |
| Multiple system atrophy (MSA) | 1.2 | 0.4 | 2 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.1 | -2.1 | |
| Neuropathy (all types) | 0.6 | 2.2 | -2.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.2 | 3.1 | 0.68 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 8.4 | 7.1 | 0.18 |
| obsessive-compulsive disorder | 4.2 | 2.8 | 0.5 |
| Osteoarthritis | 2.7 | 1.1 | 1.45 |
| Osteoporosis | 1.9 | 1.7 | 0.12 |
| pancreatic cancer | 1 | 0.3 | 2.33 |
| Parkinson's Disease | 6.4 | 4.5 | 0.42 |
| Polycystic ovary syndrome | 4.6 | 2.2 | 1.09 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.2 | 0 |
| Primary sclerosing cholangitis | 2.6 | 1.6 | 0.63 |
| Psoriasis | 2.8 | 1.9 | 0.47 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.5 | 3.2 | 0.72 |
| Rosacea | 0.3 | 1 | -2.33 |
| Schizophrenia | 5.2 | 2.4 | 1.17 |
| scoliosis | 0.6 | 0.6 | |
| Sjögren syndrome | 2.5 | 2.6 | -0.04 |
| Sleep Apnea | 1.3 | 1 | 0.3 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 0.1 | 18 |
| Stress / posttraumatic stress disorder | 3.4 | 2.2 | 0.55 |
| Systemic Lupus Erythematosus | 3.3 | 1.3 | 1.54 |
| Tic Disorder | 0.8 | 1.2 | -0.5 |
| Tourette syndrome | 1.1 | 0.3 | 2.67 |
| Type 1 Diabetes | 3 | 3 | 0 |
| Type 2 Diabetes | 7 | 6.5 | 0.08 |
| Ulcerative colitis | 5.5 | 4.4 | 0.25 |
| Unhealthy Ageing | 3.6 | 1.7 | 1.12 |
| Vitiligo | 1.3 | 1.1 | 0.18 |
